Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Other
Bioporto A/S
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Other
-kr735k
|
CAGR 3-Years
54%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Other
-kr18m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Other
-€11.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
-3%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Other?
Other
-735k
DKK
Based on the financial report for Sep 30, 2025, Bioporto A/S's Other amounts to -735k DKK.
What is Bioporto A/S's Other growth rate?
Other CAGR 5Y
24%
Over the last year, the Other growth was 78%. The average annual Other growth rates for Bioporto A/S have been 54% over the past three years , 24% over the past five years .
